CN
2025-01-16 08:22
AsymBio Congratulates Axcynsis on FDA IND Approvel of CLDN6 ADC
返回

Axcynsis Therapeutics, a strategic partner of AsymBio, announced the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors. Axcynsis is planning to initiate a Phase 1 multicentre clinical trial in the United States in 1Q 2025.

英文linkedin图 泰思诚.jpg